Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical utility of a glycosylated fibronectin test (Lumella TM ) for assessment of impending preeclampsia

7 Mar 2025

Abstract excerpt

Objective Preeclampsia is a major pregnancy complication that results in significant maternal and infant mortality and morbidity, yet difficulties remain in the diagnosis of preeclampsia based on clinical parameters alone. The objective was to assess the performance of a hand-held point-of-care (POC) immunoassay in a clinical environment for glycosylated fibronectin (GlyFn) for the prediction of preeclampsia...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Maternal and fetal healthcare
Share to Pregnancy and preeclampsia studies
Share to Preterm Birth and Chorioamnionitis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40051335
DOI: 10.1080/14767058.2025.2474674

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical utility of a glycosylated fibronectin test (Lumella TM ) for assessment of impending preeclampsiaPMID 40051335Read ↗

Glycosylated fibronectin as a biomarker for preeclampsia and preeclampsia-related complicationsSemantic proximity Read ↗

Clinical tools and biomarkers to predict preeclampsiaSemantic proximity Read ↗

Unraveling preeclampsia: Is the fibrinogen‐to‐albumin ratio the key to early risk assessment?Semantic proximity Read ↗

Review of Laboratory Testing and Biomarker Screening for PreeclampsiaSemantic proximity Read ↗

Use of Fetal Fibronectin in Clinical PracticeSemantic proximity Read ↗

Rapid and high-sensitivity screening of pregnancy complications by profiling circulating placental extracellular vesiclesSemantic proximity Read ↗

Application of a Multiplex Platform to Identify Novel Biomarkers for Pregnancy Location and ViabilitySemantic proximity Read ↗

Changes in pregnancy-related serum biomarkers early in gestation are associated with later development of preeclampsiaSemantic proximity Read ↗

Clinical Validation of a Proteomic Biomarker Threshold for Increased Risk of Spontaneous Preterm Birth and Associated Clinical Outcomes: A Replication StudySemantic proximity Read ↗

Reviewing Accuracy of First Trimester Screening for Preeclampsia Using Maternal Factors and BiomarkersSemantic proximity Read ↗

Differential Predictability of Preterm Birth Types: Strong Signals for Indicated Cases versus Limited Success in Spontaneous Preterm BirthSemantic proximity Read ↗

Comparison of Masimo Total Hemoglobin SpHb® continuous non-invasive hemoglobin monitoring device with laboratory complete blood count measurement using venous sample: Protocol for an observational substudy of the Pregnancy Risk and Infant Surveillance and Measurement Alliance Maternal and Newborn Health (PRISMA MNH) studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.